文献速递类风湿关节炎

类风湿关节炎中利妥昔单抗从原研药非医疗性转换至生物类似药的真实世界有效性经验

Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究回顾性评估了337例类风湿关节炎患者从利妥昔单抗原研药(RTX-O)非医疗性转换至生物类似药(RTX-B)的有效性,其中255例(75.7%)转换。非医疗性转换总体有效,合并症、既往生物制剂数量及RTX-O治疗史等因素与停药风险相关。

要点

  • 转换后4个月DAS28-CRP(3)与RTX-O上一周期同时点无差异。
  • 合并症和≥2种既往生物制剂DMARD与RTX-B停药风险相关。

核心结论

  • 非医疗性转换至RTX-B总体有效,转换后疾病活动度与RTX-O历史周期相当。
  • RTX-B停药风险与合并症、既往生物制剂DMARD数量及RTX-O治疗史相关,可辅助转换决策。
  • 因疗效丧失换回RTX-O的患者在短期随访中多数仍维持治疗。

研究设计与样本

  • 转换组255/337例(75.7%),继续RTX-O组82例(24.3%)。
  • 采用DAS28-CRP(3)和RTX保留率评估转换策略有效性。

主要发现

  • 转换后4个月DAS28-CRP(3)与RTX-O上一周期同一时间点无差异(配对数据可得者占60%)。
  • 因疗效丧失停用RTX-B者42/255例(16.5%),因不良事件停用者5例(2.0%)。
  • 换回RTX-O者34/255例(13.3%),其中疗效丧失30例、不良事件4例;另13/255例(5.1%)启用其他生物制剂或靶向合成DMARD。
  • 因疗效丧失换回RTX-O的30例中,28例在平均7.7个月随访时仍维持RTX-O治疗。

关键数值与推荐

  • 转换组255/337例(75.7%),继续RTX-O组82/337例(24.3%)。
  • 因疗效丧失停用RTX-B者42/255例(16.5%),因不良事件停用者5/255例(2.0%)。
  • 换回RTX-O者34/255例(13.3%),其中疗效丧失30例、不良事件4例;启用其他生物制剂或靶向合成DMARD者13/255例(5.1%)。

临床怎么用

  • 非医疗性转换至RTX-B在多数RA患者中有效,转换后可按原周期评估疾病活动度与保留情况。
  • 合并症多、既往使用≥2种生物制剂DMARD或特定RTX-O治疗史者转换后停药风险较高,决策时需个体化考量。
  • 因疗效丧失换回RTX-O后短期多数患者可维持治疗,换回策略可行。

局限性

  • 回顾性设计,非随机分组,RTX-O对照组由拒绝转换或医生指定者构成,可能存在选择偏倚。
  • 转换后4个月DAS28-CRP(3)配对数据仅60%可得。
  • 单中心真实世界数据,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of non-medical switch from rituximab originator (RTX-O) to biosimilar (RTX-B) in patients with RA. METHODS: Between October 2017 and October 2019, all patients on RTX-O in our centre requiring re-treatment were switched to RTX-B unless declined by the patient or specified by the treating clinician. Switch strategy effectiveness was assessed retrospectively using DAS28-CRP(3) and RTX retention, with patients remaining on RTX-O as a comparator group. RESULTS: The number of patients switching to RTX-B was 255/337 (75.7%) while 82 (24.3%) remained on RTX-O. There was no difference in DAS28-CRP(3) 4 months post-RTX-B switch vs the same time point post-RTX-O previous cycle (paired data available in 60%). Eighteen-month retention estimates were 75.6% (95% CI: 69.4, 80.7%) for RTX-B group and 82.3% (95% CI: 70.4, 89.8%) for RTX-O [adjusted hazard ratio 1.52 (95% CI: 0.85, 2.73)]. The number of patients who discontinued RTX-B for loss of effectiveness (LOE) was 42/255 (16.5%), five (2.0%) for adverse effects (AEs). Risk of RTX-B discontinuation was associated with comorbidities and ≥2 previous biologic DMARDs. Risk of adverse outcome RTX cessation was associated with comorbidities, and reduced risk with number of previous RTX-O cycles and pre-switch cycle B cell depletion. The number of patients who switched back to RTX-O was 34/255 (13.3%) (LOE: 30, AEs: 4), while 13/255 (5.1%) started other biologic/targeted synthetic DMARDs. Of patients who switched back for LOE, 28/30 remained on RTX-O at a mean 7.7 months follow-up. CONCLUSION: Non-medical switch to RTX-B was largely effective. Factors associated with RTX-B discontinuation, including comorbidities, previous biologic DMARDs, and RTX-O treatment history, may inform switch decisions. Most patients who switched back to RTX-O for LOE remained on treatment at short-term follow-up.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Melville AR, Md Yusof MY, Fitton J, et al. Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2021. PMID: 33432358. doi:10.1093/rheumatology/keaa834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。